IRIS
ARCAINI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.229
EU - Europa 3.007
AS - Asia 1.853
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 8
SA - Sud America 7
AF - Africa 5
Totale 9.119
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.191
CN - Cina 1.774
IE - Irlanda 1.110
FI - Finlandia 416
UA - Ucraina 412
IT - Italia 335
DE - Germania 238
SE - Svezia 188
FR - Francia 152
GB - Regno Unito 98
IN - India 47
CA - Canada 33
BE - Belgio 22
IR - Iran 11
RU - Federazione Russa 11
TR - Turchia 9
AU - Australia 8
EU - Europa 8
BR - Brasile 5
NL - Olanda 5
RO - Romania 5
AT - Austria 4
PL - Polonia 4
CH - Svizzera 3
IL - Israele 3
JP - Giappone 3
SV - El Salvador 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CL - Cile 2
ID - Indonesia 2
MU - Mauritius 2
NG - Nigeria 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
EG - Egitto 1
ES - Italia 1
HR - Croazia 1
LV - Lettonia 1
MD - Moldavia 1
MS - Montserrat 1
MX - Messico 1
MY - Malesia 1
SG - Singapore 1
Totale 9.119
Salva come PNG Salva come JPEG
Città #
Dublin 1.107
Chandler 1.022
Jacksonville 580
Nanjing 522
Ashburn 326
Princeton 222
Lawrence 204
Nanchang 201
Wilmington 184
Beijing 173
Hebei 172
Medford 144
Shenyang 139
Changsha 133
Ann Arbor 129
Helsinki 129
Jiaxing 122
New York 111
Tianjin 91
Boardman 76
Hangzhou 71
Shanghai 58
Milan 56
Pavia 54
Los Angeles 40
Pune 40
Seattle 38
Woodbridge 36
Falls Church 35
Norwalk 33
Washington 23
Brussels 22
Verona 22
Toronto 17
Fairfield 16
Des Moines 13
San Francisco 13
Auburn Hills 10
Jinan 10
Renton 10
Zhengzhou 10
Brescia 9
Guangzhou 7
Houston 7
Kunming 7
Ningbo 7
Redwood City 7
Lanzhou 5
Paris 5
Taizhou 5
Tappahannock 5
Varese 5
Berlin 4
Brossard 4
Falkenstein 4
Fuzhou 4
Istanbul 4
Leawood 4
London 4
Melbourne 4
Redmond 4
Brugherio 3
Chicago 3
Cork 3
Florence 3
Jaguariúna 3
Las Vegas 3
Lugano 3
Monmouth Junction 3
Novokuznetsk 3
Raffadali 3
Rome 3
San Salvador 3
Zanjan 3
Ancona 2
Aprilia 2
Ardabil 2
Bologna 2
Borgomanero 2
Bronx 2
Casatenovo 2
Castelverde 2
Cerignola 2
Como 2
Dearborn 2
Delhi 2
Dello 2
Edmonton 2
Ferentino 2
Fiesole 2
Genoa 2
Haikou 2
Havant 2
Manchester 2
Mantova 2
Meldola 2
Montreal 2
Novara 2
Paratico 2
Sonneberg 2
Totale 6.610
Salva come PNG Salva come JPEG
Nome #
Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study 142
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. 90
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 88
FLIPI2: A New Prognostic Index For Follicular Lymphoma Developed By The International Follicular Lymphoma Prognostic Factor Project (IFLPFP) 85
Splenic nodal and extranodal marginal zone lymphoma: features of bone marrow involvement. 84
Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients 81
Antibiotic therapy-induced remission of bladder mucosa-associated lymphoid tissue (MALT) lymphoma carrying t(11;18)(q21;q21) apoptosis inhibitor 2-MALT1. 78
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 75
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 75
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 75
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 72
B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution 69
Blast phase of essential thrombocythemia: A single center study. 69
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 69
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 68
An insidious presentation of splenic marginal zone lymphoma 68
CD5(-) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case 67
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and nontoxic treatment for advanced follicular and mantle cell lymphoma 67
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT 66
Transient response of myeloma clone to pamidronate therapy 66
Absence of MYD88 L265P mutation in blastic plasmacytoid dendritic cell neoplasm 66
Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma 65
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 65
Peripheral arterial vascular function at altitude: sea-level natives versus Himalayan high-altitude natives 63
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection 63
Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. 63
Pharmacokinetic behavior of Rituximab: a study of different schedules of administration for heterogeneous clinical settings. 62
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance 61
Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. 61
Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features. 60
Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection. 60
A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma 59
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia 59
Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers 59
Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk 59
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 58
Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas. 58
MYD88 L265P somatic mutation in Waldenstrom’s Macroglobulinemia 58
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 57
Splenic marginal zone lymphoma: hydra with many heads? 57
Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. 57
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 57
Haematological modifications after acute exposure to high altitude: possible implications for detection of recombinant erythropoietin misuse 57
A young woman with microcytic anemia and hypertransaminasemia 57
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 56
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 56
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 55
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 55
Depletion of circulating IgM memory B cells predicts unfavourable outcome in COVID-19 55
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma 54
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms 54
Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. 54
Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection 53
Effects of breathing control on cardiocirculatory modulation in Caucasian lowlanders and Himalayan Sherpas 53
Role of the molecular staging and response in the management of follicular lymphoma patients 53
Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities. 53
Risk stratification for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH level and extrahilar lymphadenopathy: development and validation on 593 cases 53
R-CVP vs R-CHOP vs R-FM for the initial treatment of patients with advanced stage Follicular Lymphoma. Results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi (FIL) 53
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 53
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making 52
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy 52
Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). 52
Bone marrow assessment in asymptomatic immunoglobulin M monoclonal gammopathies. 52
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. 52
Everolimus in diffuse large B-cell lymphomas 52
Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up 52
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): A phase 2, randomised, multicentre trial 52
The krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. 52
Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease 51
Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease 51
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience 51
Il ruolo del trapianto autologo nei linfomi non-Hodgkin indolenti 51
Reduced hypoxic ventilatory response with preserved blood oxygenation in yoga trainees and Himalayan Buddhist monks at altitude: evidence of a different adaptive strategy? 50
A paraumbilical lymphomatous mass 50
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. 50
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 50
Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas 50
Immunochemotherapy with rituximab, vincristine and 5-days cyclophosphamide (R-CV) for heavily pretreated follicular lymphoma 50
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 50
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 49
Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. 49
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma 49
Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy 49
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 48
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. 48
Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. 48
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 48
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 48
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction 48
The NOTCH pathway is recurrently mutated in diffuse large B cell lymphoma associated with hepatitis C virus infection. 48
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma 47
Nongastric marginal zone B-cell lymphoma of MALT: prognostic value of disease dissemination 47
Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors 47
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma 47
Antiviral therapies for managing viral hepatitis in lymphoma patients 47
Risk of second cancer in nongastric marginal zone B-cell lymphomas of MALT: a population-based study from Northern Italy 47
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. 47
Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas 47
Eosinophilic folliculitis occurring in a patient affected by Hodgkin lymphoma. 47
Splenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report 46
Totale 5.828
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.008
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.008
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201921 0 0 0 0 0 0 0 0 0 3 5 13
2019/20202.000 638 843 1 75 6 81 19 86 5 177 60 9
2020/20211.009 98 70 21 79 10 169 14 178 106 124 115 25
2021/2022973 22 5 19 15 38 55 19 56 54 40 140 510
2022/20233.008 280 196 21 241 280 320 27 176 1.267 29 112 59
2023/20241.233 145 236 60 99 104 406 34 87 12 50 0 0
Totale 9.600